(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2...alian Government has announced that it will be spe...ird flu drug Relenza from Biota Holdings. //Austra...er yesterday. The drug had been licensed by Biota...e, but Biota had alleged that GSK failed to market...
...ddenly collapsed on a family in Karawal Nagar area...e children and two adults and injuring four others...ng beside the wall of a school building, which had...eting deputy commissioner of police R.L Meena said...
... Suk the cloning pioneer of South Korea is defendi... upon the editors of Science magazine in Washingto... US scientific magazine, Donald Kennedy said that ...ertainly not ... months' to explain and support hi...
...puncture, Ayurveda, Chinese movement therapies suc...ng are just some of the commonly used alternative ... over Europe. //Perhaps, this is because it’s stro...e conventional medical treatment for cancer with t...
Other Medicine News:Health News:Scientist Calls Upon Media To Retract His Work 2(Date:9/3/2008)...ollow up results from chronically infected Hepatit... data obtained earlier in 2008, - Study is the f...term antiviral effect of therapeutic Hepati...gly support move into a second generation, vaccin...ing through TLR acti...
(Date:9/3/2008)...Company to Discuss Phase 3 Plans with FDA, PRINCE...ics, Inc.,announced today that it successfully co... of the company,s new, innovative low-dose, once-w...rs to by its internal product,code AG-200-15. The ...t its,primary endpoint of ovulation suppression, c...
(Date:9/2/2008)...t. 3 /- Forest Laboratories...A. today announced results from,two global Phase I...ing,inhaled anticholinergic for the treatment of p... (COPD). In both the ACCLAIM/COPD I&II,(AClidinium...oderate to,Severe COPD Patients) studies, once-dai...
(Date:9/2/2008)...Meets Primary Bone Mineral Density and Secondary E...Company to Host Conference Call and Webcast Wednes...am ET / 5:30 am PT, SAN DIEGO, Sept. 2 /PRNewswir...aq: NBIX ) today announced positive safety and ef...ial using its proprietary, orally-active,nonpeptid...
Breaking Medicine Technology:Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6A tricky tumor virus 9695 1A tricky tumor virus 9695 2Just hours apart 2 brothers undergo robotic prostate cancer surgery 9693 1Just hours apart 2 brothers undergo robotic prostate cancer surgery 9693 2Relatives who decline organ donations face conflict and guilt 9691 1Relatives who decline organ donations face conflict and guilt 9691 2Relatives who decline organ donations face conflict and guilt 9691 3New gene test for prostate cancer at hand 9689 1New gene test for prostate cancer at hand 9689 2...DALE, Fla.--(BUSINESS WIRE)--May 9, 2007 - Regener...unced positive,results from several studies evalua...age-related macular degeneration (wet AMD) and,dia...sented this,week at the annual meeting of the Asso...ARVO). The data reported at the meeting,from a pre...
...CO--(BUSINESS WIRE)--May 9, 2007 - Results of a Ph...NKTR-061 (inhaled,amikacin) to treat hospital acqu...sented at the American Thoracic Society (ATS),Inte...ancisco., ,WHO: Dr. Michael S. Niederman, MD,...hrop-University Hospital, Professor of, ...
Other Medicine Technology:VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 2VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 3VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 4VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting 5Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
...tory and a worldwide leader in innovative laborato...ive test menu of highly complex and unique medical...y the University of Utah, ARUP Laboratories' clien...ty teaching hospitals and children's hospitals, ma...
Medicine Products: